Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3959 Target Snapshot

Ribosyldihydronicotinamide dehydrogenase [quinone] · SINGLE PROTEIN · Homo sapiens

661Compounds
88Assays
19Approved Drugs
664.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P16083. Use UniProt P16083 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P16083 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribosyldihydronicotinamide dehydrogenase [quinone] as ChEMBL target CHEMBL3959, mapped to UniProt P16083. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribosyldihydronicotinamide dehydrogenase [quinone]
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3959
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P16083
Ribosyldihydronicotinamide dehydrogenase [quinone]
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ribosyldihydronicotinamide dehydrogenase [quinone] is the right protein anchor across sources, using UniProt P16083 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRibosyldihydronicotinamide dehydrogenase [quinone]
UniProt AccessionP16083
Component TypeProtein
Sequence Length231 aa

Ribosyldihydronicotinamide dehydrogenase [quinone]

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Ribosyldihydronicotinamide dehydrogenase [quinone], mapped to UniProt P16083. Sequence length is 231 aa.

Mapped IDP16083
Review nameRibosyldihydronicotinamide dehydrogenase [quinone]
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

19
Approved
13
Phase III
12
Phase II
9
Phase I
Assay Mix

Activity Type Distribution

IC50363.0
KI56.0
KD245.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL300056 10.06 Ki 0.088 Preclinical
CHEMBL300056 10.05 IC50 0.08913 Preclinical
CHEMBL300728 9.89 IC50 0.1288 Preclinical
CHEMBL300728 9.89 Ki 0.13 Preclinical
CHEMBL52559 9.74 Ki 0.18 Preclinical
CHEMBL52559 9.7 IC50 0.1995 Preclinical
CHEMBL511675 9.52 IC50 0.302 Preclinical
CHEMBL53622 9.51 IC50 0.309 Preclinical
CHEMBL53622 9.51 Ki 0.31 Preclinical
CHEMBL1770214 9.41 IC50 0.39 Preclinical
Distribution

pChEMBL Value Distribution

77
5.0
57
5.5
77
6.0
37
6.5
70
7.0
29
7.5
13
8.0
6
8.5
1
9.0
8
9.5
pChEMBL
Approved Drugs

Approved Drugs

PACRITINIB
CHEMBL2035187
Approved 2022
TEPOTINIB
CHEMBL3402762
Approved 2020
MELATONIN
CHEMBL45
Approved 2007
NILOTINIB
CHEMBL255863
Approved 2007
IMATINIB
CHEMBL941
Approved 2001
PRAZOSIN
CHEMBL2
Approved 1976
Assay Landscape

Assay Landscape

88
Total Assays
386
Tested Compounds
1
Assay Types
Binding — 88 assays, 386 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 48 146 6.3
cell-based format 19 48 7.5
assay format 18 157 5.9
microsome format 2 0
subcellular format 1 35 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine